Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

Overview of attention for article published in Journal for Immunotherapy of Cancer, March 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (60th percentile)

So far, Altmetric has seen 10 X posts from 7 X users, with an upper bound of 39,097 followers.

#JITC Research: Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab https://t.co/y5DxbQ5f50 https://t.co/KU40gGya1M

RT @sitcancer: #JITC Research: Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved o…

RT @sitcancer: #JITC Research: Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved o…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 6 additional X posts.